Results 251 to 260 of about 8,290,554 (306)
Some of the next articles are maybe not open access.
Psoriasis induced by biological therapy
Reumatología Clínica (English Edition), 2021To describe a multicentre case series of new onset or worsening of psoriasis in patients treated with biological drugs.Descriptive study. We reviewed the clinical history of patients with chronic inflammatory disease (CID) treated with biological drugs, who developed new onset or worsening of psoriasis during the follow-up period.Twenty-six cases of ...
Montolio Chiva L +5 more
openaire +4 more sources
YouTube for information about side effects of biologic therapy: A social media analysis
International Journal of Rheumatic Diseases, 2020Biologic therapies are one of the most significant breakthroughs in the treatment of rheumatic diseases, although there is still some uncertainty surrounding long‐term patient safety. Recently, a growing number of patients browse the Internet as a source
Mustafa Erkut Önder, Orhan Zengin
exaly +2 more sources
Biologic therapies in the vasculitides
Current Opinion in Rheumatology, 2003Monoclonal antibody and recombinant DNA technologies have led to the development of biologic therapies capable of directly targeting selected components of the immune response. With the steady expansion of knowledge regarding the mechanisms of vascular inflammation, the safety and efficacy of biologic agents in the vasculitic diseases are being ...
Carol A, Langford, Michael C, Sneller
openaire +2 more sources
Inflammatory Bowel Diseases, 2007
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
Biological therapies in otology
HNO, 2017Hearing loss is present in millions of people worldwide. Current treatment for patients with severe to profound hearing loss consists of cochlear implantation. Providing the cochlear nerve is intact, patients generally benefit greatly from this intervention, frequently achieving significant improvements in speech comprehension. There are, however, some
A, Roemer +4 more
openaire +2 more sources
Journal of Infusion Nursing, 2012
Biologic therapy includes a diverse group of drugs that act directly on the immune system. Sometimes referred to as "targeted therapy," the biologics include cytokines and monoclonal antibodies. These agents can be genetically engineered versions of naturally occurring substances, or novel compounds used for the treatment of cancer and for nononcology ...
openaire +2 more sources
Biologic therapy includes a diverse group of drugs that act directly on the immune system. Sometimes referred to as "targeted therapy," the biologics include cytokines and monoclonal antibodies. These agents can be genetically engineered versions of naturally occurring substances, or novel compounds used for the treatment of cancer and for nononcology ...
openaire +2 more sources
Biological Therapies in Osteoarthritis
Current Pharmaceutical Design, 2015Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification.
Claire Y J, Wenham +2 more
openaire +2 more sources
Seminars in Respiratory and Critical Care Medicine, 2018
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach
Journal of Clinical MedicineAsthma is a highly heterogeneous respiratory disease that, in its severe forms, is characterized by persistent symptoms, frequent exacerbations, and a significant impact on patients’ quality of life.
M. D'Amato +11 more
semanticscholar +1 more source
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
JAAD Case Reports, 2019 Numerous biologic medications are available to treat psoriasis and psoriatic arthritis; however, many patients experience differential responses of their skin and joints to the same agent.
Vidhatha Reddy +2 more
exaly +2 more sources